Dr. McReynolds is an experienced sEHI researcher, and co-founder of EicOsis. She has previously managed preclinical efforts through Phase II clinical trials for start-up and semi-virtual biotech companies.

Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 4 biotech companies.

Dr. Heather Hsu has more than 20 years of pharmaceutical/biotech industry experience with research, nonclinical development and clinical pharmacology. She has built, participated in and led teams of skilled professionals that have brought multiple drugs from discovery through to clinical proof of concept. Including participating in regulatory filings and communication for drugs in clinical development through to approval. Her drug development work includes programs including but not limited to oncology, inflammatory and cardiometabolic diseases at companies including Johnson and Johnson and Gilead Sciences as well as small companies.

Dr. Cortés-Puch is a critical care medicine physician and researcher with expertise in clinical trial design and monitoring, translational medicine, quality improvement, and regulatory communications. She spent 5 years conducting translational research at the National Institutes of Health and is currently a scientist at the UC Davis Division of Pulmonary and Critical Care Medicine.

Dr. Hwang is a synthetic chemist with expertise in the design, synthesis, and characterization of small molecules in medicinal chemistry. He leads the development of highly potent inhibitors of epoxide hydrolase and cyclooxygenase enzymes.

Dr. Yang is an analytical chemist with expertise in the DMPK and analyses of small molecules in medicinal chemistry. He leads the research on DMPK of highly potent inhibitors of epoxide hydrolase and biomarker assessment.

Shahar is an operations and finance executive with a career in both the public and private sectors. Extensive experience in operations strategic planning and execution, project management, leadership, and budgeting. Expertise in Ag and Bio technologies with emphasis on laboratories, IoT deployment and maintenance, and food supply chains. Shahar holds a bachelor’s degree in agriculture economics (Cum Lauda) from the Hebrew university in Jerusalem Israel and Executive MBA from Kellogg School of Management (Northwestern University)

Krystal is a project manager with a background ranging from biotech startups to global tech to the nonprofit sector. She holds a B.S. in Biology with a minor in Chemistry from the University of North Texas and is currently pursuing Project Management certification. Her experience includes supporting early-stage biotech companies, managing high-paced projects, and coordinating cross-functional teams in both scientific and administrative settings.

Dr. Hammock was a Distinguished Professor at the University of California, Davis. Dr. Hammock was an elected member of the National Academy of Sciences, US (1999), until his passing in January, 2026. He had over 30 years of extensive experience in the field of eicosanoids that yielded over 1000 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors. Dr. Hammock leaves a legacy of excellence in science, devotion to mentoring, and innovation in pharmaceuticals.

Dr. McReynolds is an experienced sEHI researcher, and co-founder of EicOsis. She has previously managed preclinical efforts through Phase II clinical trials for start-up and semi-virtual biotech companies.